High-dose therapy for autoimmune neurologic diseases.

Area of Science:

• Neurology
• Immunology
• Oncology (Stem Cell Transplantation)

Background:

• Autoimmune neurologic diseases are increasingly recognized.
• Conventional immunosuppressive agents are often insufficient for refractory cases.
• High-dose therapy with or without stem cell transplantation is an emerging treatment option.

Purpose of the Study:

• To review the rationale, methods, and recent results of high-dose therapy for autoimmune neurologic diseases.
• To discuss the potential role of high-dose therapy in managing refractory conditions.
• To identify key questions and future directions for this treatment modality.

Main Methods:

• Review of existing literature on high-dose therapy for autoimmune neurologic diseases.
• Analysis of various immune ablation techniques, including those requiring hematopoietic stem cell transplantation.
• Consideration of high-dose cyclophosphamide as an immunoablative, non-myeloablative option.

Main Results:

• High-dose therapy has shown encouraging, durable responses in refractory cases of multiple sclerosis, myasthenia gravis, and autoimmune neuropathies.
• While not universally effective, the treatment offers a valuable option for patients unresponsive to conventional immunotherapy.
• Treatments carry risks and have been primarily reserved for severe, refractory conditions.

Conclusions:

• High-dose therapy, with or without stem cell transplantation, is a valuable resource for refractory autoimmune neurologic diseases.
• Defining optimal patient selection, treatment methods, and timing is crucial for maximizing benefits.
• High-dose therapy may become a standard treatment for severe progressive autoimmune neurologic disorders in the future.